Viatris Total Cost of Revenue decreased by 7.7% to $2.36B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.7%, from $2.09B to $2.36B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows a downward trend with a -6.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.25B | $2.96B | $2.80B | $2.42B | $2.41B | $2.33B | $2.60B | $2.19B | $2.31B | $2.25B | $2.24B | $2.16B | $2.35B | $2.29B | $2.31B | $2.09B | $2.25B | $2.39B | $2.56B | $2.36B |
| QoQ Change | — | -8.8% | -5.6% | -13.4% | -0.3% | -3.5% | +11.7% | -15.9% | +5.6% | -2.6% | -0.4% | -3.6% | +8.9% | -2.5% | +0.9% | -9.5% | +7.5% | +6.2% | +7.0% | -7.7% |
| YoY Change | — | — | — | — | -25.7% | -21.4% | -6.9% | -9.7% | -4.3% | -3.4% | -13.9% | -1.3% | +1.8% | +1.8% | +3.2% | -3.1% | -4.3% | +4.2% | +10.5% | +12.7% |